Michael D. Pak

Array ( [id] => 18685180 [patent_doc_number] => 11780898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Treatment of SMC mediated disease [patent_app_type] => utility [patent_app_number] => 16/158528 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 86 [patent_no_of_words] => 40222 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16158528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16892135 [patent_doc_number] => 11033662 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Treatment of ischemia and reperfusion using leptin antagonist [patent_app_type] => utility [patent_app_number] => 16/153890 [patent_app_country] => US [patent_app_date] => 2018-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 49 [patent_no_of_words] => 28278 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16892135 [patent_doc_number] => 11033662 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Treatment of ischemia and reperfusion using leptin antagonist [patent_app_type] => utility [patent_app_number] => 16/153890 [patent_app_country] => US [patent_app_date] => 2018-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 49 [patent_no_of_words] => 28278 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16892135 [patent_doc_number] => 11033662 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Treatment of ischemia and reperfusion using leptin antagonist [patent_app_type] => utility [patent_app_number] => 16/153890 [patent_app_country] => US [patent_app_date] => 2018-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 49 [patent_no_of_words] => 28278 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16892135 [patent_doc_number] => 11033662 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Treatment of ischemia and reperfusion using leptin antagonist [patent_app_type] => utility [patent_app_number] => 16/153890 [patent_app_country] => US [patent_app_date] => 2018-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 49 [patent_no_of_words] => 28278 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815610 [patent_doc_number] => 11421209 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Cells producing Fc containing molecules having altered glycosylation patterns and methods and use thereof [patent_app_type] => utility [patent_app_number] => 16/153257 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 37 [patent_no_of_words] => 22498 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14105057 [patent_doc_number] => 20190094204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => MEMBRANE TRANSPORTER ASSAY AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/138249 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16138249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14045935 [patent_doc_number] => 20190079074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => STEP-FUNCTION CHANNELRHODOPSINS FOR OPTICAL CONTROL OF CELLS [patent_app_type] => utility [patent_app_number] => 16/126384 [patent_app_country] => US [patent_app_date] => 2018-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16126384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14018983 [patent_doc_number] => 20190071485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => Novel Substitution Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System [patent_app_type] => utility [patent_app_number] => 16/117211 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16117211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14230519 [patent_doc_number] => 20190127432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => GLYCOPROTEIN HORMONE LONG-ACTING SUPERAGONISTS [patent_app_type] => utility [patent_app_number] => 16/116080 [patent_app_country] => US [patent_app_date] => 2018-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17056 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16116080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793405 [patent_doc_number] => 20190010241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 16/104434 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16104434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273817 [patent_doc_number] => 20190134193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS [patent_app_type] => utility [patent_app_number] => 16/059662 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16059662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090507 [patent_doc_number] => 20200199240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/631655 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826595 [patent_doc_number] => 20190016782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => STABLE FORM OF SIGNAL CONVERTING PROTEIN FUSION PROTEINS, AND METHODS OF USE AND PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/027382 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16027382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17220711 [patent_doc_number] => 11173194 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-16 [patent_title] => Inotropic antibodies and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 15/985514 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 14442 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15985514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19310489 [patent_doc_number] => 12036283 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods [patent_app_type] => utility [patent_app_number] => 16/613757 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 99 [patent_no_of_words] => 28140 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13604111 [patent_doc_number] => 20180353604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 15/969896 [patent_app_country] => US [patent_app_date] => 2018-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15969896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522553 [patent_doc_number] => 20180312819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => PROTEIN INHIBITORS TO COMPLEMENT AND VEGF PATHWAYS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/965382 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13510473 [patent_doc_number] => 20180306779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => METHOD FOR EVALUATING ACTIVITY OF G PROTEIN-COUPLED RECEPTOR (GPCR) [patent_app_type] => utility [patent_app_number] => 15/957406 [patent_app_country] => US [patent_app_date] => 2018-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15957406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368855 [patent_doc_number] => 20180235968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => EGFR MUTATIONS [patent_app_type] => utility [patent_app_number] => 15/954541 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954541 [rel_patent_id] =>[rel_patent_doc_number] =>)